CervoMed reports Q3 2026 results and neflamapimod pipeline progress across four programs
The company detailed data, regulatory steps, and a new dosing regimen across dementia with Lewy bodies, FTD, ALS, and stroke recovery programs, while cash stood at $19.6 million.
CervoMed Inc. reported financial results for the third quarter ended September 30, 2026, along with updates across its neflamapimod clinical programs, in a release dated November 9, 2026.
In dementia with Lewy bodies (DLB), neflamapimod was awarded Innovation Passport designation under the United Kingdom Innovative Licensing and Access Pathway in August 2026, a designation designed to support accelerated time to market and help expedite patient access.1 In September 2026, the company announced pharmacokinetic data on a 50mg oral tablet formulation and said the FDA removed a prior neflamapimod drug exposure limit for future trials, supporting use of a 100mg BID dosing regimen that the company said is expected to achieve target trough plasma drug concentrations in nearly all patients.1 In October 2026, results from the Phase 2b RewinD-LB trial were published in Alzheimer's Research & Therapy, and translational biomarker findings were published in Cells.1
In FTD, CervoMed presented initial 12-week biomarker results from its Phase 2a trial in nonfluent variant primary progressive aphasia in October 2026, showing a reduction in mean plasma neurofilament light chain levels.1 24-week biomarker data from this trial are set for presentation at CTAD 2026, taking place November 16-19, 2026 in Boston.1 The company expects to report initial 24-week clinical data in March 2027 and full topline data in the second quarter of 2027.1
CervoMed completed enrollment of 45 patients in the Phase 2a RESTORE trial in acute ischemic stroke recovery1, with topline data expected by the end of 2026.1 Dosing of the first ALS patient under the EXPERTS-ALS trial is expected in the first quarter of 2027.1
Financially, cash, cash equivalents, and marketable securities were approximately $19.6 million as of September 30, 2026, down from $20.9 million at year-end 2025, which the company said should fund operations through the third quarter of 2027.1 Net loss was approximately $5.9 million for the quarter, versus $7.7 million a year earlier.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.